Adalimumab, sold under the brand name Humira, enjoyed a long run as one of the world's best-selling medicines. But its 20-year, competition-free period has ended, and despite its best efforts to delay ...

(Reuters) -Coherus BioSciences Inc said on Thursday it plans to launch a biosimilar of AbbVie Inc's Humira in July at a list price of $995 per carton, representing a discount of about 85% from the ...

Adalimumab is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and ...

Meitheal, a biopharmaceutical company focused on developing and commercializing generic injectables, fertility, biologic and branded products, has gained exclusive U.S. commercial rights to Yusimry, a ...